Changes in complement alternative pathway components, factor B and factor H during dengue virus infection in the AG129 mouse

Sheila Cabezas-Falcon, Aidan J. Norbury, Jarrod Hulme-Jones, Sonja Klebe, Penelope Adamson, Penny A. Rudd, Suresh Mahalingam, Li-Ching Ong, Sylvie Alonso, David L. Gordon and Jillian M. Carr

Abstract

The complement alternative pathway (AP) is tightly regulated and changes in two important AP components, factor B (FB) and factor H (FH) are linked to severe dengue in humans. Here, a mouse model of dengue was investigated to define the changes in FB and FH and assess the utility of this model to study the role of the AP in severe dengue. Throughout the period of viremia in the AG129 IFN signalling-deficient mouse, an increase in FB and a decrease in FH was observed following dengue virus (DENV) infection, with the former only seen in a model of more severe disease associated with antibody-dependent enhancement (ADE). Terminal disease was associated with a decrease in FB and FH, with greater changes during ADE, and accompanied by increased C3 degradation consistent with complement activation. In silico analysis of NFκB, signal transducer and activator of transcription (STAT) and IFN-driven FB and FH promoter elements to reflect the likely impact of the lack of IFN-responses in AG129 mice, demonstrated that these elements differed markedly between human and mouse, notably with mouse FH lacking NFκB and key IFN-stimulated response elements (ISRE), and FB with many more NFκB and STAT-responsive elements than human FB. Thus, the AG129 mouse offers utility in demonstrating changes in FB and FH that, similar to humans, are associated with severe disease, but lack predicted important human-specific and IFN-dependent responses of FB and FH to DENV-infection that are likely to regulate the subtleties of the overall AP response during dengue disease in humans.

INTRODUCTION

Dengue virus (DENV) is a mosquito-borne flavivirus for which there are four distinct serotypes, (DENV-1–4) [1, 2]. Infection with DENV can result in clinical presentations ranging from a febrile illness (dengue) to more severe disease (dengue with warning signs) and life-threatening disease with increased vascular permeability and haemorrhagic manifestations [3, 4]. Severe dengue is more likely to occur during a second infection with a heterologous serotype [5, 6], where the cross-reactive but not cross-protective immunity contributes to severe disease by mechanisms such as antibody-dependent enhancement (ADE) of infection [7]. Additionally, the immune response contributes to disease via other mechanisms. For instance, the primary pathology of dengue vascular leak syndrome is mediated by dysregulated vasoactive cytokine and chemokine responses, such as TNF-α [8, 9], and actions of the viral NS1 protein on the vascular endothelium [10, 11]. Cleavage products generated during complement activation similarly contribute to the dysregulated inflammatory response during DENV-infection [12, 13]. The complement system involves a cascade of protein cleavages that generate sequentially activated downstream proteins involved in targeting non-self components for lysis by the membrane attack complex (MAC) [14]. Additionally, complement cleavage products have direct vasoactive and chemotactic actions [15, 16]. There are three arms of the complement pathway; the classical pathway (CP), lectin...
pathway (LP) and alternative pathway (AP) [14]. While all three pathways can be activated by recognition of danger signals associated with infection, the AP is constitutively active but tightly regulated to prevent damage to the host [17]. There are several activators and regulators of the AP [18], with key roles played by factor B (FB), as a driver of formation of the active C3b convertase complex (C3bBb) during which process both C3 and FB are cleaved [19], and factor H (FH), a negative regulator of C3 convertase formation and activity [20]. As such, high levels of AP activity are associated with complement consumption, and low levels of complement substrates such as FB and C3 [21, 22]. Low levels or mutations in FH are also associated with over-activity of the AP and complement-mediated diseases of the vasculature and kidneys, such as atypical haemolytic uremic syndrome (a-HUS) [23] and C3 glomerulopathies [24].

DENV interacts with the complement system on a number of levels: the LP or C1q from the CP recognizes DENV virions and protects against infection [25–27], and disruption of this recognition by non-neutralizing antibody links loss of complement control with ADE and disease severity [28]. Further, DENV NS1 protein interacts with complement components, such as C1s and C4 to evade the CP and LP activation [29, 30], and with vitronectin and clusterin to inhibit terminal-pathway MAC formation [31, 32]. Interestingly, while West Nile Virus NS1 binds FH, the negative regulator of the AP, DENV NS1 does not [33, 34], suggesting that DENV does not evade the AP in the same way as other flaviviruses. Consistent with this, severe dengue is associated with increased activity of the complement AP, specifically an increase in circulating levels of the anaphylatoxins C3a and C5a [21, 22], an increase in factor D (FD) and a decrease in circulating FH [13]. Using in vitro models, our laboratory has shown increased activity of the AP during DENV-infection in the local environment of DENV-infected macrophages and endothelial cells, with increases in FB but not FH protein and increased C3b deposition on cells [35].

To further investigate the complement AP during DENV-infection, changes in FB and FH in a mouse model of DENV-infection were defined. Results support that in the IFN-deficient AG129 mouse model where disease severity can be experimentally modulated by ADE, FB and FH are temporally altered during DENV-infection, with the magnitude of these changes associated with disease severity. IFN, STAT and NFκB responsive promoter elements are important predicted regulators of FB and FH in humans and many of these promoter elements differ in mice and would not be activated in the AG129 IFN-receptor deficient mouse model. Thus, the available DENV AG129 mouse models may not reflect the overall AP-DENV interaction but still demonstrates complement responses associated with disease severity and may be useful to dissect the roles of specific factors controlling the AP during DENV-infection.

METHODS
Clinical cohort
Human serum samples from DENV-seropositive and seronegative healthy patients form part of a retrospective descriptive study [36]. These samples were collected over a 13 month period between 1 January 2014 and 31 January 2015 and sera was obtained from archival material stored at −20°C. Serological analysis of DENV IgM/IgG/NS1 was performed by Dengue Duo assay (SD BIOLINE) and reverse transcription (RT)-PCR and serotype identified by PCR, as described [36]. The current study includes 10 DENV-seronegative and 29 DENV-seropositive patients from the total cohort encompassing DENV-1, -2 and -3 serotypes [36].

FH and FB ELISA
Human or mouse FH proteins were quantitated in sera using an in-house ELISA as previously described [35]. In brief, 96-well microtitre plates were coated with goat anti-human FH at 10 μg ml−1 or sheep anti-mouse FH antibody at 2.5 mg ml−1. Human and mouse serum were diluted 1:1000 and 1:500, respectively, in PBS+1% (w/v) bovine serum albumin (BSA). A mouse anti-human FH or a rat monoclonal anti-mouse FH diluted 1:10000 were used as detection antibodies for FH. Standard curves with purified human FH (10–400 ng ml−1) or commercial recombinant mouse FH (20–200 ng ml−1) were used producing a linear regression curve (R² >0.99). Human FH ELISA had an intra- and inter-assay co-efficient of variation of 6.04 and 11.57%, respectively, while mouse FH ELISA had intra- and inter-assay coefficients of variation of 4.24 and 10.98%, respectively.

The levels of human or mouse FB were measured using the Human FB (ab137973, Abcam) or the mouse FB (SECO11Mu, Cloud-Clone) ELISA kits, respectively, in accordance with the manufacturer’s instructions.

DENV-AG129 mouse-infection model of dengue disease
Mouse infections utilized DENV-2 strain, D2Y98P-PP1, isolated from a patient in Singapore during 2005 (GenBank accession no. JF327392) and stocks were amplified in C6/36 cells. Cell-culture supernatants containing virus were harvested, clarified, filtered (0.22 μM, Sartorius) and stored at −80°C until use. The titre of infectious virus was determined by plaque assay using Vero cells and quantitated as p.f.u. per ml. Then, 5–6-week-old AG129 mice (129/Sv strain deficient in IFN-α/β and IFN-γ receptors) were mock-infected or infected subcutaneously with 10⁴ of the DENV-2 strain, D2Y98P-PP1. The clinical signs were scored: 1=ruffled fur, 2=hunched back, 3=severe diarrhoea, 4=lethargic, 5=moribund [37]. Serum, liver and kidney samples were harvested at day 2 and 4 post infection (p.i.) when the animals were humanely euthanized. Each group of animals consisted of n=6 mice except for the day 4 p.i. group where n=7. All tissue samples were collected directly into TRIzol reagent for RNA extraction and sera and tissue samples stored at −80°C prior to analysis.
DENV-AG129 mouse-infection model with ADE and severe dengue disease

Five–six-week-old AG129 mice born from previously DENV-1 (05K3903DK1, 10^6 p.f.u., subcutaneously) infected, but convalesced mothers or DENV-naïve mothers, were either mock-infected (n=3 each) or infected subcutaneously with 10^3 p.f.u. of D2Y98P-PP1 DENV-2 (n=5 each), as described previously [37]. In brief, the DENV-immune model involved infection of 6-week-old female AG129 mice with a non-lethal dose of a DENV-1 strain, followed by mating 1 week later and delivery of pups. Clinical signs were scored as described above. As previously reported [37], day 6 post-DENV2 infection the DENV-naïve mice had a mean disease score of 2/5 and 100% survival while mice born to DENV1-immune dams had a mean disease score of 5/5 and were ethically euthanized at this time point. Animals from the latter group contained elevated levels of circulating DENV RNA, increased vascular leakage in the intestine, liver, spleen and kidney, and increased serum levels of cytokines and chemokines including TNF-α [37].

Serum samples were collected at day 3 and day 6 p.i. Liver and kidney samples were harvested at day 6 p.i. into TRIzol reagent for RNA extraction and samples stored at −80 °C.

RT-PCR

Total RNA was extracted from mouse tissues using TRIZol, DNase I treated and 0.5 µg RNA was reverse transcribed with 60 µM random hexamers and M-MuLV reverse transcriptase. The cDNA template was subjected to real-time qRT-PCR using iTaq SYBER green in a Rotor-gene 6000 (Corbett Research), using primers listed in Table 1. All PCRs were performed under the following conditions: one cycle of 95°C for 5 min; 40 cycles of 95°C for 15 s, 59°C for 30 s, and 72°C for 30 s; and one cycle of 72°C for 5 min, except mouse FB PCR, which was annealed at 60°C. All PCR reactions included high and low copy number comparative controls. Results were normalized against the reference housekeeping genes: cyclophilin or glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The relative RNA level was determined by ΔCt method as described [38].

SDS-PAGE and Western blot

To quantitate total protein, 2 µl of mouse sera was subjected to electrophoresis on Mini-PROTEAN TGX stain-free gels (Biorad), images collected (ChemiDOC gel imaging system, BioRad) and total protein quantitated using Image J. For analysis of C3, 2 µl of sera was subjected to SDS-PAGE (8%, 30:1 acrylamide: bis) and Western blot to nitrocellulose. Membranes were probed with rabbit anti-C3 antibody (Abcam Ab97462, 1/2000) and secondary goat anti-rabbit IgG-horse radish peroxidase conjugate (Pierce, 1/25000). Bound complexes were detected by chemiluminescence (BioRad, Clarity Max ECL) with signal detected (ChemiDOC gel imaging system, BioRad) and images analysed (Image J) [39].

Histological analysis

Mouse kidneys were harvested and fixed in 10% (v/v) buffered formalin, embedded and block mounted in paraffin. Sections were cut to 1 µm thickness, stained with haematoxylin and eosin (H and E) or Periodic-acid Schiff (PAS) stain. Sections were assessed by brightfield microscopy by an anatomical pathologist.

Matinspector FB and FH promoter analysis

The Genomatix MatInspector software was used for in silico prediction of potential transcription-factor binding sites in the human and mouse FB and FH promoters. The MatInspector programme contains an in-built library comprising 634 matrices of transcription-factor binding sites with around 366000 human, and mouse promoter sequences [40, 41]. MatInspector analysis for FB and FH was performed using sequence data for promoters associated with at least one verified coding transcript. Stringent criteria were set with a core similarity value of 0.75 and an optimized matrix similarity threshold of 0.8 (where the core sequence of a matrix, or binding site, of 1 reflects identity). To refine these initial matches down to the most probable transcription-factor binding sites, those with a matrix similarity higher than 0.85 and with at least one line of

| Target | Sequence | Accession no. | Amplicon size (bp) |
|--------|----------|---------------|--------------------|
| DENV-2 | F: GCAGATCTCTGTGATAATACAAAC<br>R: TTGTCAAGTGTGTAACATG | NM_AF038403.1 | 102 |
| Pan DENV | F: AAGGACTAGAGGTAKAAGGAGACCC<br>R: CGYTCTGTGTGTAACATG | NM_AF038403.1 | 102 |
| m-GAPDH | F: GACGGCCGCTACCTCTCCTGTC<br>R: TGCCACTGCAAATGGACCC | NM_008084.3 | 120 |
| m-FH | F: CGTGAATGTGGTGACAGATGGG<br>R: AGAATTACACACCATCCTGTC | NM_009888.2 | 248 |
| m-FB | F: CTCTCTTGGAGGGTGTGACCG<br>R: GGTCTGGCGGCAGCTATTG | NM_008198.2 | 264 |

m=mouse, F=forward; R=reverse; bp=base pairs. Y=C/T; K=G/T; W=A/T.
supporting evidence in Matinspector, such as experimental validation of the binding site, or a literature citation linking the transcription factor with FH or FB were considered.

Statistical analysis

Results were expressed as the mean±sd, and statistical analyses were performed using a two-tailed unpaired Student t-test, one-way or two-way ANOVA or the non-parametric Kruskall–Wallis test for data that was not normally distributed or contained low values of n. Statistical analysis was performed using GraphPad Prism, version 8 (GraphPad, La Jolla, CA, USA). Differences were considered statistically significant if P<0.05.

RESULTS

Changes in FB and FH are associated with dengue infection in AG129 mice

To study the interaction of DENV with FB and FH in the context of severe disease a model of DENV-infection of AG129 mice, lacking IFN-α, -β and -γ receptors, was utilized in (i) an acute setting where animals succumb after the decline in viremia [42, 43] and (ii) a model of more severe disease, reflecting ADE induced by pre-existing maternal antibody and leading to a fatal disease with onset closely after the peak in viremia [37, 44]. In the model of acute DENV-infection with viremia over 2–6 days p.i. (Fig. 1a), circulating FB protein levels were unchanged while in contrast, circulating FH was slightly but significantly decreased at day 4 p.i. (Fig. 1b). This was accompanied by an increase in liver mRNA for both FB and FH at day 4 p.i. (Fig. 1c), while mRNA levels in the kidney were unchanged (Fig. 1d).

In a model of dengue ADE, mice born to DENV-1 immune mothers are challenged with DENV-2 and develop a fatal disease with haemorrhage by day 6 p.i. that is more severe than DENV-2 infection in mice born to DENV-naïve mothers [37, 43]. Consistent with this, DENV liver RNA levels quantitated by RT-PCR were significantly higher in DENV-infected born to DENV-immune compared to DENV-infected born to DENV-naïve mice (Fig. 2a). Additionally, DENV-infected mice have higher circulating total protein levels (50–100 kDa range) as quantitated by gel electrophoresis of serum and stain-free imaging (Fig. 2b). This potentially reflects reduced blood volume secondary to the described vascular leak in both models, although does not reflect the greater vascular leak described with more severe disease in the DENV-immune model compared with DENV-naïve mice [37, 43].

Next, circulating FB and FH levels were quantitated by ELISA at day 3 and 6 p.i. in this model. Results demonstrate a small but significant increase in FB and decrease in FH at day 3 p.i. in DENV-2-infected born to DENV-1-immune mothers (Fig. 3a). In contrast, at day 6 p.i., FB is decreased, and FH concentration increased in the circulation with a significantly greater change in FH in DENV-2-infected
mice born to DENV-1-immune compared to DENV-naive mothers (Fig. 3b). Given the increased protein concentration in blood at day 6 p.i. (Fig. 2b), results were normalized against total circulating protein, demonstrating an even greater decline in FB but negating the apparent increase and demonstrating a significant decrease in FH (Fig. 3c). No change was seen in mRNA for FB or FH in the kidney or liver at day 6 p.i. (data not shown).

To further define complement activation, circulating C3 was assessed by Western blot at day 6 p.i. Bands representing the potential C3/C3b-α-chain (114 kDa), C3 β-chain (75 kDa) and C3 degradation productions (C3d, C3dg, 35–40 kDa) were observed (Fig. 4a). In DENV-infected animals the profile of C3 degradation products was different with increased C3d/dg in both DENV-naive and immune mice (Fig. 4a). Quantitation of C3 β-chain or C3 d/dg (data not shown) demonstrated lower levels of C3 immunoreactivity in DENV-2-infected mice born to DENV-1-immune but not naïve mothers (Fig. 4b). Since complement-mediated pathology often manifests in the kidney, kidneys harvested at day 6 p.i. were fixed, stained and analysed by light microscopy. Representative images are shown (Fig. 4c). Kidneys showed no pathological damage, specifically no increase in glomerular obsolescence, identifiable thickening of basement membrane on PAS- or silver stains (data not shown), tram-tracking or spiking and no mesangial expansion or increase in cellularity. There was no extracapillary proliferation, no tubular damage and no proteinaceous casts identified. There was no evidence of vasculitis, granulomas, viral inclusions, papillary necrosis and no interstitial inflammation.

Changes in factor B and factor H are not observed in clinical samples from primary dengue patients

Studies in humans have shown changes in FB and FH in the context of DHF/DSS but not dengue fever [13]. Here circulating FB and FH were quantitated by ELISA in a cohort of 39 returned travellers for whom there was a clinically requested DENV serological test and reflecting primary, non-severe dengue fever [36]. Samples were grouped in accordance with DENV serology as DENV-seronegative or DENV-seropositive for any of NS1/IgM or IgG. Samples were further stratified clinically into (i) DENV-seronegative for whom no significant clinical diagnosis or laboratory findings were reported (e.g. benign headache, afebrile, C-reactive protein [CRP] < 8 mg l⁻¹ with normal full blood examination results), (Fig. 5a, DENV negative, healthy); (ii) DENV-seronegative who demonstrated a clinically relevant infectious diagnosis (e.g. Salmonella enterica infection), or laboratory result such as elevated white-cell count or CRP, (Fig. 5a, DENV negative, ill); and (iii) DENV-seropositive and clinically diagnosed with dengue fever, representing a cohort of adults with primary dengue infection and a febrile illness, as described previously (Fig. 5a, DENV positive, dengue) [36]. FB was significantly elevated in the DENV seronegative, ill group, relative to the DENV-seronegative, healthy controls or the DENV-seropositive group, (Fig. 5a). No significant changes in FH were observed in any group (Fig. 5a). Within the DENV-seropositive group, FB and FH were positively correlated (P = 0.04, r = 0.4) but neither correlated with laboratory parameters: platelet, total white cell, lymphocyte, neutrophil and monocyte counts, or CRP (data not shown). The DENV-seropositive group was stratified further based on DENV NS1/IgM/IgG serology and the presence of circulating viral RNA: 22/29 samples were DENV RT-PCR positive with the exceptions as indicated (Fig. 5b) and the majority of infections presented as RT-PCR, NS1 and/or IgM positive and thus in the early stages of infection. Most infections were DENV-1 and -2 with one DENV-3 case [36]. Although numbers in some groups were small, no significant difference or trend was observed in FB or FH levels in any DENV-seropositive group (Fig. 5b). This confirms the prior reported lack of change in circulating FB and FH during non-severe dengue, re-enforcing that the changes in FB and FH are likely specific for severe disease in humans [12, 13] and as shown here also in mice with severe dengue.

To assess potential species-specific responses of FB and FH to infection, the promoters of mouse and human FB and FH were compared with a particular focus on inflammatory and IFN-driven responses.

Transcriptional regulation of FB and FH differs in human and mouse and is regulated by IFN

In silico analysis of the mouse and human FB promoter using MatInspector demonstrated NFkB, STAT and IRFF matrix family elements. Proximal STAT elements were present in both human and mouse promoters with overall more elements present in the mouse FB promoter (Fig. 6a). The mouse FB promoter contains five proximal IRF elements but only three,
Fig. 3. FB and FH in AG129 mice infected with DENV +/- ADE. Five- to six-week-old AG129 mice born to either DENV-1-immune (immune) or dengue-naïve (naïve) mothers were uninfected (ui, \( n=3 \) each group) or subcutaneously infected with \( 10^3 \) p.f.u. of DENV-2 strain D2Y98P-PP1 (DENV, \( n=5 \) each group). Blood and tissue was harvested, serum collected and subjected to ELISA for quantitation of FB and FH protein levels at (a) day 3 p.i. and (b) day 6 p.i.; (c) normalization of circulating FB and FH at day 6 p.i., against total protein from Fig. 2b. *\( P<0.05 \), one-way ANOVA/Tukey’s test.
more distal elements are found in the human promoter. The mouse FB promoter contains four predicted NFκB sites around the −300 region and a further three >−600 while the human FB promoter contains only two NFκB binding sites at around −600 relative to the transcription start site (Fig. 6a). For the IRFF family, IRF4 and 7 are predicted to regulate both mouse and human FB promoters, while IRF1 and IRF3 transcription-factor binding sites are present in the mouse but not human FB promoter (Table 2). Of note, STAT3 binding sites were predicted in the mouse FB promoter, while this transcription factor was not predicted in the human FB promoter (Table 2). Overall, the mouse FB promoter contains more potential STAT and IRF transcription-factor binding sites and many more NFκB binding sites than the human FB promoter (Table 2).

Predicted dependency on IRFF and STAT regulation is seen with the human and mouse FH promoter. Strikingly no NFκB or ISRE binding sites are predicted in the mouse FH promoter (Fig. 6b, Table 2). Several common members of the
IRF and STAT families were predicted in both the human and mouse FH promoters (Table 2), with IRF4 and 7, STAT5 and 6 predicted in the FH promoters from both species (Table 2). IRF1 was predicted in the human and IRF2 and IRF3 in the mouse FH promoter only. Overall, there is a lack of ISRE, IRF1 and NFκB transcription-factor binding sites in the mouse compared to the human FH promoter (Table 2). Together with the FB analysis these findings predict IFN as an important regulator of these genes and that mouse and human FB and FH are likely to respond differently to infectious challenges that stimulate IFN.

**DISCUSSION**

Complement is vital for pathogen control and the complement system is required for protection against DENV-infection. The AP, however, is dysregulated and may be part of the pathology of dengue disease with lower levels of circulating FB in patients with severe DENV disease during the shock period [21, 22], and reduced FH in DHF patients compared to dengue fever patients or healthy individuals [13].

Here changes in FB and FH were defined during severe disease, to assess changes in these proteins and define the utility of an available mouse model of dengue to study the AP. Immunocompetent mice are poorly susceptible to DENV-infection and disease since the virus fails to block anti-viral signalling pathways in mouse cells [45]. AG129 mice lacking type I and II IFN receptors are permissive to DENV-infection resulting in disease with some similarities to dengue in humans [43, 46], while a model of DENV-infection in mice born to mothers with heterotypic DENV immunity induces severe dengue, as seen during secondary infection in humans and reflecting ADE [37]. In the DENV-AG129 mouse-infection model where mice survive the acute viremia, circulating FB protein levels are unchanged while FH protein was reduced at day 4 p.i. In a more severe dengue model with ADE of infection, the mice succumb to disease at day 6 p.i. concomitant

---

**Fig. 5.** Circulating FB and FH levels in a human cohort of non-severe dengue. Samples sent for diagnostic DENV serology were analysed for FB and FH by ELISA. (a) Samples were grouped based on serology and clinical diagnosis as DENV-seronegative healthy (n=5), DENV-seronegative ill (n=5) and DENV-seropositive (n=29); (b) DENV-seropositive samples were stratified based on NS1, IgM and IgG status. Samples that were RT-PCR negative are indicated by grey dots. FB (upper panel) and FH (lower panel) were assessed by ELISA. Differences between groups were analysed by Kruskal–Wallis test, and are indicated by **P<0.05.
Fig. 6. Predicted transcription-factor binding sites in the FB and FH promoters. Schematic localization of the NFκB, IRFF and STAT transcription-factor binding sites in the mouse and human (a) FB and (b) FH promoter sequences. Transcription-factor binding sites were identified using MatInspector software with core similarity of >0.85.

Table 2. Comparison of NFκB, IRFF and STAT binding elements in the human and mouse FB and FH promoters

| Specific factor | NFκB | IRF1 | IRF2 | IRF3 | IRF4 | IRF7 | ISRE | STAT | STAT1 | STAT3 | STAT5 | STAT5A | STAT5B | STAT6 |
|----------------|------|------|------|------|------|------|------|------|-------|-------|-------|--------|--------|-------|
| Human FB       | 2    | -    | -    | -    | 2    | 1    | -    | 2    | -     | -     | -     | -       | -       | 1     |
| Mouse FB       | 7    | 1    | -    | 1    | 1    | 2    | -    | 3    | 1     | 6     | -     | 1       | -       | -     |
| Human FH       | 1    | 1    | -    | -    | 1    | 1    | 2    | 1    | -     | -     | 1     | 2       | 3       | 1     |
| Mouse FH       | -    | -    | 1    | 1    | 1    | 1    | -    | 2    | -     | -     | 2     | 2       | 2       | 1     |
with viremia, and this is associated with an early increase in FB (day 3 p.i.) while FH levels significantly decrease. Later in infection, circulating FB levels decrease (day 6 p.i.) while FH demonstrates an apparent increase in concentration that is associated with a generalized increase in circulating protein. When normalized for total protein, circulating levels of FH are actually decreased.

The changes in FB and FH are significantly greater in mice defined previously to have more severe disease when infected under ADE conditions [37, 43]. The early increase in FB and subsequent decrease at terminal disease stage in mice is consistent with activation of FB as an acute phase reactant, then subsequent decrease in FB due to complement consumption, in agreement with the decline in FB observed in DHF patients during the shock phase [21, 22]. The early decrease in FH levels in mice is consistent with findings of reduced FH in DHF cases [13]. While direct quantitation of C3 split products C3a or C3b would have also been of value here, our findings of reduced C3 and increased C3 low molecular weight fragments (C3dg), are consistent with complement activation [47] and the above described changes in FB and FH. C3 levels have previously been shown to be reduced in severe dengue [21], and are lower in patients with DHF compared to DF [13]. Thus, the AG129 dengue-mouse model appears to reflect FB, FH and C3 changes described in the literature in association with severe dengue disease in humans. Consistent with this, in our human cohort of non-severe dengue changes appear to be mediated by post-translational consumption (FB) or haemoconcentration (FH). DENV-6 transcription factors. STAT5 can be activated by members of the IL-2 (IL-2, IL-7, IL-15, IL-21) and IL-3 families (IL-3, IL-5) [52] and IL-2, IL-21 and IL-5 are known to be induced in patients with DF and DHF [53]. The mouse FB promoter contains six predicted STAT3 responsive elements that are not present in the human FB promoter. IL-6, a cytokine significantly elevated in DENV-infected AG129 mice [37, 43] and associated with disease in humans is an activator of STAT3 [54, 55] and thus this is a pathway unique in the mouse that may induce FB during DENV-infection. Thus, in the context of DENV-infection, NFκB and STAT-responsive elements are likely to be activated and be important in disease, and the human and mouse FB and FH promoters have different capacities to respond to this. This suggests that the mouse model may not be a good reflection of inflammatory drivers of FB and FH during DENV-infection.

Additionally, our promoter analysis has demonstrated various IRFF promoter elements with inherent differences in human and mouse FB and FH promoters. Specifically, IRF4 and 7 are present across human and mouse FB and FH promoters. The expression of IRF4 is restricted to T- and B-cell lineages [56–58] and thus unlikely to be important directly in DENV-infected cells. IRF7 and IRF3 are considered the master regulators of type I IFN responses, with expression of IRF7 dependent on IFN-α/β signalling [59, 60] and thus, IRF7-driven responses will be absent in the AG129 mouse model. The mouse FB and FH promoters have IRF3 binding sites, but these are not found in either of the human promoters. Further, the human FH promoter contains two ISREs, key elements in induction of ISGs which are not present in the mouse FH promoter. Similarly, IRF1 is unique to the human FH promoter while the mouse FH promoter contains a unique IRF2 binding site. Together these results suggest that the mouse promoters differ to human in likely important NFκB, STAT and IFN-regulated elements that are anticipated to drive FB and FH responses during DENV-infection.

Thus, the AG129 IFN-receptor deficient mouse elicits some changes in FB and FH that correlate with disease severity in a manner similar to that seen during severe DENV-infection in humans but differs in promoter elements that control IFN- and NFκB-driven FB and FH responses that are predicted to be important. Alternative DENV-susceptible mouse models such as IFNAR−/− [61], deficient only in IFNγ receptor, could be utilized to further study roles for specific factors, such as IFNγ in FB and FH responses. Additionally, the AG129 model could benefit the study of IFN-independent induction of acute complement responses to differing virus inoculum for instance from mosquito compared to mammalian sources with differing glycosylation patterns and potential ability to activate...
complement. Human cohorts, however, with well-defined timing of infection and well characterized disease severity and physiological correlates, remain a good source of data to define the changes and likely roles of FB and FH during DENV-infection.

Funding information
This project was supported by a Flinders Foundation Seed Grant (JMC, DLOi); SC-F was supported by an Australian International Postgraduate Research Scholarship.

Acknowledgements
The authors thank Dr Amanda Lumsden for assistance with the Matin-spector Programme, Dr Geoff Higgins and Ms Trish Hahesy for provi-sion of patient samples.

Author contributions
Conceptualization (S.C.F., D.L.G., J.M.C.); data curation (S.C.F.); formal analysis (S.C.F., A.J.N., J.H.-J., S.K., J.M.C.); funding acquisition (J.M.C., S.M., S.A.); investigation (S.C.F., A.J.N., J.H.-J., L.C.O., P.A.R.); methodology (S.C.F., A.J.N., J.H.-J., L.C.O., P.A.R., J.M.C.); project administration (J.M.C.); resources (J.M.C., S.M., D.L.G., P.A.R.); supervision (J.M.C., S.M., S.A.); validation (J.M.C.); writing – original draft (S.C.-F., J.M.C.); writing – review and editing (J.M.C., D.L.G., S.M., S.A., P.A.R., J.H.-J., A.J.N., S.K.).

Conflicts of interest
The authors declare that there are no conflicts of interest.

Ethical statement
Sera from the clinical cohort was collected and used in accordance with Southern Adelaide Clinical Human Research Ethics Committee approval 134/15 and 200/16 and in accordance with the World Medical Association Declaration of Helsinki. AG129 mouse experiments were performed under the guidelines of the National Advisory Committee for Laboratory Animal Research (NACLAR) under licence to operate in accredited animal facilities with IACUC/NUS protocol approval number R13-4751 and in accordance with approval from Griffith University Animal Welfare Committee, approval number GLY/11/14/AEC.

References
1. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998;11:480–496.
2. Sabin AB. The dengue group of viruses and its family relationships. Bacteriol Rev 1950;14:225–232.
3. WHO. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control, New Edition. Geneva: WHO Guidelines Approved by the Guidelines Review Committee; 2009.
4. Halstead SB. Dengue. Lancet 2007;370:1644–1652.
5. Halstead SB, O’Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977;265:739–741.
6. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000;181:2–9.
7. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003;60:421–467.
8. Carr JM, Hocking H, Bunting K, Wright PJ, Davidson A et al. Supernatants from dengue virus type-2 infected macrophages induce permeability changes in endothelial cell monolayers. J Med Virol 2003;69:521–528.
9. Chen Y-C, Wang S-Y. Activation of terminally differentiated human monocytes/macrophages by dengue virus: productive infection, hierarchical production of innate cytokines and chemokines, and the synergistic effect of lipopolysaccharide. J Virol 2002;76:9877–9887.
10. Beatty PR, Puerta-Guardo H, Killingbeck SS, Glasner DR, Hopkins K et al. Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Sci Transl Med 2015;7:304ra141.
11. Modhiran N, Watterson D, Muller DA, Panetta AK, Sester DP et al. Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity. Sci Transl Med 2015;7:304ra142.
12. Nascimento EJM, Hottz ED, Garcia-Bates TM, Bozza F, Marques ETA et al. Emerging concepts in dengue pathogenesis: interplay between plasmablasts, platelets, and complement in triggering vasculopathy. Crit Rev Immunol 2014;34:227–240.
13. Nascimento EJM, Silva AM, Cordeiro MT, Brito CA, Gil LHVG et al. Alternative complement pathway deregulation is correlated with dengue severity. PLoS One 2009;4:e7472.
14. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Compl-ement system Part I - molecular mechanisms of activation and regulation. Front Immunol 2015;6:262.
15. Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement system Part II: role in immunity. Front Immunol 2015;6:257.
16. Kemper C, Pangburn MK, Fishelson Z. Complement nomenclature 2014. Mol Immunol 2014;61:56–58.
17. Walport MJ. Complement. first of two parts. N Engl J Med 2001;344:1058–1066.
18. Ricklin D, Hajishengallis G, Yang K, Lambiris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010;11:785–797.
19. Milder FJ, Gomes L, Schouten A, Janssen BJ, Huizinga EG et al. Factor B structure provides insights into activation of the central protease of the complement system. Nat Struct Mol Biol 2007;14:224–228.
20. Weiler JM, Daha MR, Austen KF, Fearon DT. Control of the amplification convertase of complement by the plasma protein betaH. Proc Natl Acad Sci U S A 1976;73:3268–3272.
21. Bokisch VA, Top FH, Russell FK, Müller-Eberhard HJ, Müller- Eberhard HJ. The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N Engl J Med 1973;289:996–1000.
22. Churdboonchart V, Bhamarapravati N, Futrakul P. Crossed immuno-electrophoresis for the detection of split products of the third complement in dengue hemorrhagic fever. I. observations in patients’ plasma. Am J Trop Med Hyg 1983;32:569–576.
23. Zhang K, Lu Y, Harley KT, Tran M-H. Atypical hemolytic uremic syndrome: a brief review. Hematol Rep 2017;9:7053.
24. Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol 2011;2:634–642.
25. Avirutnan P, Hauhart RE, Marovich MA, Garred P, Atkinson JP et al. Complement-mediated neutralization of dengue virus requires mannose-binding lectin. mBio 2011;2 [Epub ahead of print 13 12 2011].
26. Duradinh B, McBurney SP, Soares de Melo KM, Smith AP, Krishna NK et al. C1q binding to dengue virus decreases levels of infection and inflammatory molecules transcription in THP-1 cells. Virus Res 2014;179:231–234.
27. Fuchs A, Lin T-Y, Beasley DW, Stover CM, Schwaebe WJ et al. Direct complement restriction of flavivirus infection requires glycan recognition by mannose-binding lectin. Cell Host Microbe 2010;8:186–195.
28. Mehlohp E, Ansarah-Sorbinho C, Johnson S, Engle M, Fremont DH et al. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2007;2:417–426.
29. Avirutnan P, Fuchs A, Hauhart RE, Somnuk P, Youn S et al. Antag-omism of the complement component C4 by flavivirus nonstruc-tural protein NS1. J Exp Med 2010;207:793–806.
30. Avirutnan P, Hauhart RE, Somnuk P, Blom AM, Diamond MS et al. Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation. J Immunol 2011;187:424–433.
31. Conde JN, da Silva EM, Alonzo D, Coelho DR, Andrade Idas et al. Inhibition of the membrane attack complex by dengue virus NS1
through interaction with vitronectin and terminal complement proteins. J Virol 2016;90:9570–9581.

32. Kurosu T, Chaichana P, Yamate M, Anantapreeca S, Ikuta K. Secreted complement regulatory protein clusterin interacts with dengue virus nonstructural protein 1. Biochem Biophys Res Commun 2007;352:1051–1056.

33. Chung KM, Liszewski MK, Nybakken G, Davis AE, Townsend RR et al. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci U S A 2006;103:19111–19116.

34. Kraivong R, Vasanawathana S, Limpitikul W, Malasit P, Tangthawornchaikul N et al. Complement alternative pathway genetic variation and dengue infection in the Thai population. Clin Exp Immunol 2013;174:326–334.

35. Cabezas S, Bracho G, Aloia AL, Adamson PJ, Bonder CS et al. Dengue virus induces increased activity of the complement alternative pathway in infected cells. J Virol 2018;92 [Epub ahead of print 15 07 2018].

36. Quinn EJ, Cheong AH-C, Calvert JK, Higgins G, Hahey T et al. Clinical features and laboratory findings of travelers returning to South Australia with dengue virus infection. Trop Med Infect Dis 2018;3:6–14.

37. Ng JKW, Zhang SL, Tan HC, Yan B, Martinez JM et al. First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies. PLoS Pathog 2014;10:e1004031.

38. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative (C(T)) method. Nat Protoc 2008;3:1101–1108.

39. Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ. 25 years of image analysis. Nat Methods 2012;9:671–675.

40. Quandt K, Frech K, Karas H, Wingender E, Werner T, Matlind WT. Matlnspector and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995;23:4878–4884.

41. Carcharius K, Frech K, Grote K, Kloccke B, Haltmeier M et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005;21:2933–2942.

42. Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR et al. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol 2004;78:2701–2710.

43. Tan GK, Ng JKW, Trasti SL, Schul W, Yip G et al. A non-mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl Trop Dis 2010;4:e672.

44. Lee PX, Ong LC, Libau EA, Alonso S. Relative contribution of dengue IgG antibodies acquired during gestation or breast-feeding in mediating dengue disease enhancement and protection in type I interferon receptor-deficient mice. PLoS Negl Trop Dis 2016;10:e0004805.

45. Zompis S, Harris E. Animal models of dengue virus infection. Viruses 2012;4:62–82.

46. Williams KL, Zompis S, Beatty PR, Harris E. A mouse model for studying dengue virus pathogenesis and immune response. Ann N Y Acad Sci 2009;1171 Suppl 1:E12–23.

47. Troldborg A, Jensen L, Deleuran B, Stengaard-Pedersen K, Thiel S et al. The C3dg fragment of complement is superior to conventional C3 as a diagnostic biomarker in systemic lupus erythematosus. Front Immunol 2018;9:581.

48. Carlin AF, Plummer EM, Vizcarra EA, Sheets N, Joo Y et al. An IFR-3-, IFR-5-, and IFR-7-Independent pathway of dengue viral resistance utilizes IRF-1 to stimulate Type I and II interferon responses. Cell Rep 2017;21:1600–1612.

49. Li X-Q, Li XN, Liang J-J, Cai X-B, Tao Q et al. IRF1 up-regulates ISG15 gene expression in dsRNA stimulation or CSFV infection by targeting nucleotides -487 to -325 in the 5’ flanking region. Mol Immunol 2018;94:153–165.

50. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011;472:481–485.

51. Pastor AF, Rodrigues Moura L, Neto JWD, Nascimento EJM, Calzavara-Silva CE et al. Complement factor H gene (CFH) polymorphisms C-257T, G257A and haplotypes are associated with protection against severe dengue phenotype, possible related with high CFH expression. Hum Immunol 2013;74:1225–1230.

52. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002;285:1–24.

53. Maneekan P, Leangwutwong P, Misse D, Luplertlop N. T helper (Th) 1 and Th2 cytokine expression profile in dengue and malaria infection using magnetic bead-based bio-plex assay. Southeast Asian J Trop Med Public Health 2013;44:31–36.

54. Chua JJ-E, Bhuvanakantham R, Chow VT-K, Ng M-L. Recombinant non-structural 1 (NS1) protein of dengue-2 virus interacts with human Stat3beta protein. Virus Res 2005;112:85–94.

55. Chen M, Sun F, Han L, Qu Z. Kaposi’s sarcoma herpesvirus (KSHV) microRNA K12-1 functions as an oncogene by activating NF-κB/IL-6/STAT3 signaling. Oncotarget 2016;7:33363–33373.

56. Nakaya T, Sato M, Hata N, Asagiri M, Suemori H et al. Gene induction pathways mediated by distinct IRFs during viral infection. Biochem Biophys Res Commun 2001;283:1150–1156.

57. Sato M, Taniguchi T, Tanaka N. The interferon system and interferon regulatory factor transcription factors – studies from gene knockout mice. Cytokine Growth Factor Rev 2001;12:133–142.

58. Zhang X, Zhang Z, He S, Fu Y, Chen Y et al. Foxo3, IRF4, and xIAP are correlated with immune activation in HIV-1-infected men who have sex with men during early HIV infection. AIDS Res Hum Retroviruses 2017;33:172–180.

59. Marié I, Durbin JE, Levy DE. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. Embo J 1998;17:6660–6669.

60. Sato M, Hata N, Asagiri M, Nakaya T, Taniguchi T et al. Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett 1998;441:106–110.

61. Prestwood TR, Morar MM, Zellweger RM, Miller R, May MM et al. Gamma interferon (IFN-γ) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-α/β receptor-deficient mice. J Virol 2012;86:12561–12570.

---

Five reasons to publish your next article with a Microbiology Society journal

1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around the world.
4. 80% of our authors rate our submission process as ‘excellent’ or ‘very good’.
5. Your article will be published on an interactive journal platform with advanced metrics.

Find out more and submit your article at microbiologyresearch.org.